IUPAC stringlengths 5 167 | SMILES stringlengths 1 1.53k | Description stringlengths 2 54.3k | PID stringlengths 3 9 |
|---|---|---|---|
Streptozocin | [C@@H]1([C@H](O)C(CO)OC(O)[C@@H]1NC(=O)N(N=O)C)O | Classic European guidelines for the management of advanced low-grade pNET recommend [C@@H]1([C@H](O)C(CO)OC(O)[C@@H]1NC(=O)N(N=O)C)O plus 5-fluorouracil/doxorubicin or, currently, temozolomide, with or without capecitabine, as chemotherapy, and everolimus or sunitinib as targeted agents. Although treatment with chemoth... | 9448188 |
Temozolomide | n1cn2c(n(C)nnc2c1C(N)=O)=O | Classic European guidelines for the management of advanced low-grade pNET recommend streptozocin plus 5-fluorouracil/doxorubicin or, currently, n1cn2c(n(C)nnc2c1C(N)=O)=O, with or without capecitabine, as chemotherapy, and everolimus or sunitinib as targeted agents. Although treatment with chemotherapy results in respo... | 9448188 |
Everolimus | C[C@@H]1/C=C/C=C/C=C(/[C@H](C[C@H]2O[C@@]([C@H](C)CC2)(O)C(=O)C(=O)N2CCCC[C@H]2C(O[C@H]([C@H](C)C[C@@H]2CC[C@H]([C@@H](C2)OC)OCCO)CC([C@H](C)/C=C(/[C@@H](O)[C@H](C([C@@H](C1)C)=O)OC)C)=O)=O)OC)C | Classic European guidelines for the management of advanced low-grade pNET recommend streptozocin plus 5-fluorouracil/doxorubicin or, currently, temozolomide, with or without capecitabine, as chemotherapy, and C[C@@H]1/C=C/C=C/C=C(/[C@H](C[C@H]2O[C@@]([C@H](C)CC2)(O)C(=O)C(=O)N2CCCC[C@H]2C(O[C@H]([C@H](C)C[C@@H]2CC[C@H]... | 9448188 |
Sunitinib | c1(C(NCCN(CC)CC)=O)c([nH]c(/C=C2/c3c(ccc(F)c3)NC2=O)c1C)C | Classic European guidelines for the management of advanced low-grade pNET recommend streptozocin plus 5-fluorouracil/doxorubicin or, currently, temozolomide, with or without capecitabine, as chemotherapy, and everolimus or c1(C(NCCN(CC)CC)=O)c([nH]c(/C=C2/c3c(ccc(F)c3)NC2=O)c1C)C as targeted agents. Although treatment ... | 9448188 |
Etoposide | [C@@H]1([C@H](O)[C@H]([C@H]2[C@@H](CO[C@H](O2)C)O1)O)O[C@@H]1C2C(=CC3OCOC=3C=2)[C@@H](C2C=C(OC)C(=C(OC)C=2)O)[C@@H]2[C@@H]1COC2=O | As in patients with low-grade NET, recommendations for first-line therapy in patients with high-grade tumors include chemotherapy that is based on the pattern of small cell lung cancer with [C@@H]1([C@H](O)[C@H]([C@H]2[C@@H](CO[C@H](O2)C)O1)O)O[C@@H]1C2C(=CC3OCOC=3C=2)[C@@H](C2C=C(OC)C(=C(OC)C=2)O)[C@@H]2[C@@H]1COC2=O ... | 9448188 |
Everolimus | O[C@@H]1/C(=C/[C@H](C(C[C@H](OC([C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]1OC)C)C)OC)=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1)=O)C)C | O[C@@H]1/C(=C/[C@H](C(C[C@H](OC([C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]1OC)C)C)OC)=O)[C@H](C)C[C@@H]1CC[C@@H](OCCO)[C@H](OC)C1)=O)C)C, an orally administered mammalian target of rapamycin (mTOR) inhibitor, has demonstrated both clinical efficacy and acceptable t... | 9448188 |
Rapamycin | O=C1O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@@H](CC2)O)CC(=O)[C@@H](/C=C(/[C@@H](O)[C@@H](OC)C([C@@H](C[C@@H](/C=C/C=C/C=C(\C)[C@H](C[C@H]2O[C@@]([C@@H](CC2)C)(O)C(=O)C(N2[C@H]1CCCC2)=O)OC)C)C)=O)C)C | Everolimus, an orally administered mammalian target of O=C1O[C@H]([C@H](C)C[C@H]2C[C@@H](OC)[C@@H](CC2)O)CC(=O)[C@@H](/C=C(/[C@@H](O)[C@@H](OC)C([C@@H](C[C@@H](/C=C/C=C/C=C(\C)[C@H](C[C@H]2O[C@@]([C@@H](CC2)C)(O)C(=O)C(N2[C@H]1CCCC2)=O)OC)C)C)=O)C)C (mTOR) inhibitor, has demonstrated both clinical efficacy and acceptab... | 9448188 |
Everolimus | [C@H]([C@@H]1CC([C@@H](/C=C(/[C@@H](O)[C@H](C(=O)[C@H](C)C[C@@H](/C=C/C=C/C=C(\C)[C@@H](OC)C[C@H]2O[C@@](O)(C(=O)C(=O)N3[C@H](C(=O)O1)CCCC3)[C@H](C)CC2)C)OC)C)C)=O)(C[C@@H]1CC[C@H]([C@@H](C1)OC)OCCO)C | Thus, although clinical trials have investigated novel treatments for NET patients experiencing treatment failure and disease progression, data are limited on second and successive lines of treatment and are even sparser for high-grade pNET, which is usually excluded from clinical trials. The RADIANT-3 trial enrolled p... | 9448188 |
Octreotide | N1C([C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@@H](NC(=O)[C@H](NC([C@@H](N)CC2C=CC=CC=2)=O)CSSC[C@@H](NC([C@@H](NC([C@@H]1CCCCN)=O)[C@@H](C)O)=O)C(=O)N[C@@H]([C@H](O)C)CO)CC1=CC=CC=C1)=O | Thus, although clinical trials have investigated novel treatments for NET patients experiencing treatment failure and disease progression, data are limited on second and successive lines of treatment and are even sparser for high-grade pNET, which is usually excluded from clinical trials. The RADIANT-3 trial enrolled p... | 9448188 |
Octreotide | C1C=CC=CC=1C[C@@H](C(N[C@H]1C(=O)N[C@@H](CC2C=CC=CC=2)C(N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)O)C(=O)N[C@H](CSSC1)C(=O)N[C@H](CO)[C@H](O)C)=O)=O)=O)N | In June 2008, a 34-year-old woman presented with a 2-month history of epigastric and periumbilical pain, fatigue, anorexia, nausea, and emesis. Physical assessment showed mild abdominal distention with painful hepatomegaly extending to the left hypochondrium, no adenopathy, and normal findings on echocardiogram (left v... | 9448188 |
Streptozocin | O=C(N(C)N=O)N[C@H]1C(OC([C@@H](O)[C@@H]1O)CO)O | Chemotherapy was initiated with O=C(N(C)N=O)N[C@H]1C(OC([C@@H](O)[C@@H]1O)CO)O and 5-fluorouracil in July 2008; the patient received 3 cycles of this first-line chemotherapy. In September 2008, clinical and biomarker evaluation demonstrated progressive disease, and treatment was switched to second-line cisplatin and et... | 9448188 |
Cisplatin | N.N.Cl[Pt]Cl | Chemotherapy was initiated with streptozocin and 5-fluorouracil in July 2008; the patient received 3 cycles of this first-line chemotherapy. In September 2008, clinical and biomarker evaluation demonstrated progressive disease, and treatment was switched to second-line N.N.Cl[Pt]Cl and etoposide for 4 cycles. After dis... | 9448188 |
Etoposide | O(C)c1cc(cc(OC)c1O)[C@@H]1c2c(cc3OCOc3c2)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H]3O[C@H](C)OC[C@H]3O2)O)[C@H]2COC(=O)[C@H]12 | Chemotherapy was initiated with streptozocin and 5-fluorouracil in July 2008; the patient received 3 cycles of this first-line chemotherapy. In September 2008, clinical and biomarker evaluation demonstrated progressive disease, and treatment was switched to second-line cisplatin and O(C)c1cc(cc(OC)c1O)[C@@H]1c2c(cc3OCO... | 9448188 |
Doxorubicin | O(c1c2C(=O)c3c(c4c(c(O)c3C(c2ccc1)=O)C[C@@](O)(C(=O)CO)C[C@@H]4O[C@H]1C[C@@H]([C@H](O)[C@@H](O1)C)N)O)C | Chemotherapy was initiated with streptozocin and 5-fluorouracil in July 2008; the patient received 3 cycles of this first-line chemotherapy. In September 2008, clinical and biomarker evaluation demonstrated progressive disease, and treatment was switched to second-line cisplatin and etoposide for 4 cycles. After diseas... | 9448188 |
Opioids | C(N1CCC(N(C2C=CC=CC=2)C(CC)=O)CC1)CC1=CC=CC=C1.C1=CC=C(C=C1)C1(C(=O)OCC)CCN(CC1)C.C1=CC2C[C@@H]3[C@]4([C@@]5(CCN3C)C=2C(=C1OC)O[C@H]5C(=O)CC4)O | After 9 months of chemotherapy and 3 lines of therapy, the patient had a KPS of 60%, peritoneal metastases, and palpable hepatomegaly. She required high-dose C(N1CCC(N(C2C=CC=CC=2)C(CC)=O)CC1)CC1=CC=CC=C1.C1=CC=C(C=C1)C1(C(=O)OCC)CCN(CC1)C.C1=CC2C[C@@H]3[C@]4([C@@]5(CCN3C)C=2C(=C1OC)O[C@H]5C(=O)CC4)O to achieve analges... | 9448188 |
Temozolomide | C1=NC(C(=O)N)=C2N1C(N(C)N=N2)=O | After 9 months of chemotherapy and 3 lines of therapy, the patient had a KPS of 60%, peritoneal metastases, and palpable hepatomegaly. She required high-dose opioids to achieve analgesia. Fourth-line treatment with C1=NC(C(=O)N)=C2N1C(N(C)N=N2)=O (150 mg/m 2 on days 9-14) and capecitabine (1,000 mg/m 2 for 14 days ever... | 9448188 |
Paclitaxel | C1=CC([C@@H]([C@@H](O)C(=O)O[C@@H]2C(C)=C3C(C)([C@@](C2)([C@@H](OC(=O)C2C=CC=CC=2)[C@H]2[C@](C)(C(=O)[C@@H]3OC(C)=O)[C@@H](O)C[C@@H]3[C@@]2(OC(=O)C)CO3)O)C)NC(C2=CC=CC=C2)=O)=CC=C1 | In September 2009, after receiving 1 dose of fifth-line weekly C1=CC([C@@H]([C@@H](O)C(=O)O[C@@H]2C(C)=C3C(C)([C@@](C2)([C@@H](OC(=O)C2C=CC=CC=2)[C@H]2[C@](C)(C(=O)[C@@H]3OC(C)=O)[C@@H](O)C[C@@H]3[C@@]2(OC(=O)C)CO3)O)C)NC(C2=CC=CC=C2)=O)=CC=C1, the patient was hospitalized because of toxicity and general deterioration ... | 9448188 |
Morphine | C1[C@@H]2[C@]34C5=C(C=CC(O)=C5O[C@H]4[C@H](C=1)O)C[C@H]2N(CC3)C | In September 2009, after receiving 1 dose of fifth-line weekly paclitaxel, the patient was hospitalized because of toxicity and general deterioration in health. She had uncontrolled pain, esophagitis, and small bowel partial obstruction caused by peritoneal disease progression that prevented her from eating without sev... | 9448188 |
Scopolamine | C12N(C)C(CC(OC([C@H](c3ccccc3)CO)=O)C1)[C@H]1[C@@H]2O1 | In September 2009, after receiving 1 dose of fifth-line weekly paclitaxel, the patient was hospitalized because of toxicity and general deterioration in health. She had uncontrolled pain, esophagitis, and small bowel partial obstruction caused by peritoneal disease progression that prevented her from eating without sev... | 9448188 |
Butyl bromide | BrCCCC | In September 2009, after receiving 1 dose of fifth-line weekly paclitaxel, the patient was hospitalized because of toxicity and general deterioration in health. She had uncontrolled pain, esophagitis, and small bowel partial obstruction caused by peritoneal disease progression that prevented her from eating without sev... | 9448188 |
Bromide | [Br-] | In September 2009, after receiving 1 dose of fifth-line weekly paclitaxel, the patient was hospitalized because of toxicity and general deterioration in health. She had uncontrolled pain, esophagitis, and small bowel partial obstruction caused by peritoneal disease progression that prevented her from eating without sev... | 9448188 |
Dexamethasone | C12CC[C@H]3[C@H]4[C@@](C[C@H](O)[C@@]3([C@@]2(C)C=CC(C=1)=O)F)(C)[C@@](C(CO)=O)([C@@H](C4)C)O | In September 2009, after receiving 1 dose of fifth-line weekly paclitaxel, the patient was hospitalized because of toxicity and general deterioration in health. She had uncontrolled pain, esophagitis, and small bowel partial obstruction caused by peritoneal disease progression that prevented her from eating without sev... | 9448188 |
Octreotide | [nH]1cc(c2c1cccc2)C[C@@H]1NC(=O)[C@@H](NC(=O)[C@H](NC([C@@H](N)Cc2ccccc2)=O)CSSC[C@@H](NC(=O)[C@@H](NC([C@@H](NC1=O)CCCCN)=O)[C@H](O)C)C(=O)N[C@H](CO)[C@@H](C)O)Cc1ccccc1 | In September 2009, after receiving 1 dose of fifth-line weekly paclitaxel, the patient was hospitalized because of toxicity and general deterioration in health. She had uncontrolled pain, esophagitis, and small bowel partial obstruction caused by peritoneal disease progression that prevented her from eating without sev... | 9448188 |
Everolimus | C1=C/[C@H](C[C@@H](C)C(=O)[C@@H]([C@@H](/C(=C/[C@@H](C)C(=O)C[C@@H]([C@@H](C[C@H]2C[C@H]([C@H](OCCO)CC2)OC)C)OC([C@@H]2CCCCN2C(=O)C([C@@]2(O)[C@H](C)CC[C@@H](C[C@@H](/C(=C/C=C/1)C)OC)O2)=O)=O)C)O)OC)C | In September 2009, after receiving 1 dose of fifth-line weekly paclitaxel, the patient was hospitalized because of toxicity and general deterioration in health. She had uncontrolled pain, esophagitis, and small bowel partial obstruction caused by peritoneal disease progression that prevented her from eating without sev... | 9448188 |
Everolimus | [C@]12(O[C@@H](CC[C@H]1C)C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C([C@@H]([C@H](O)/C(C)=C/[C@H](C(C[C@H](OC(=O)[C@@H]1CCCCN1C(C2=O)=O)[C@@H](C[C@@H]1CC[C@@H](OCCO)[C@@H](C1)OC)C)=O)C)OC)=O)O | Fifteen days after the initiation of sixth-line therapy with [C@]12(O[C@@H](CC[C@H]1C)C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C([C@@H]([C@H](O)/C(C)=C/[C@H](C(C[C@H](OC(=O)[C@@H]1CCCCN1C(C2=O)=O)[C@@H](C[C@@H]1CC[C@@H](OCCO)[C@@H](C1)OC)C)=O)C)OC)=O)O plus octreotide LAR, the CgA concentration decreased to 1,388 n... | 9448188 |
Octreotide | [C@@H]1([C@@H](C)O)NC([C@@H](NC([C@H](Cc2c3ccccc3[nH]c2)NC([C@H](Cc2ccccc2)NC([C@@H](CSSC[C@@H](NC1=O)C(N[C@H](CO)[C@@H](C)O)=O)NC(=O)[C@@H](N)Cc1ccccc1)=O)=O)=O)CCCCN)=O | Fifteen days after the initiation of sixth-line therapy with everolimus plus [C@@H]1([C@@H](C)O)NC([C@@H](NC([C@H](Cc2c3ccccc3[nH]c2)NC([C@H](Cc2ccccc2)NC([C@@H](CSSC[C@@H](NC1=O)C(N[C@H](CO)[C@@H](C)O)=O)NC(=O)[C@@H](N)Cc1ccccc1)=O)=O)=O)CCCCN)=O LAR, the CgA concentration decreased to 1,388 ng/ml. The patient achieve... | 9448188 |
Everolimus | O[C@@]12C(C(=O)N3CCCC[C@H]3C(O[C@H]([C@H](C)C[C@@H]3CC[C@H]([C@@H](C3)OC)OCCO)CC([C@H](C)/C=C(\C)[C@H]([C@@H](OC)C([C@H](C)C[C@H](C)/C=C/C=C/C=C(/[C@H](C[C@@H](O1)CC[C@H]2C)OC)C)=O)O)=O)=O)=O | Throughout the course of O[C@@]12C(C(=O)N3CCCC[C@H]3C(O[C@H]([C@H](C)C[C@@H]3CC[C@H]([C@@H](C3)OC)OCCO)CC([C@H](C)/C=C(\C)[C@H]([C@@H](OC)C([C@H](C)C[C@H](C)/C=C/C=C/C=C(/[C@H](C[C@@H](O1)CC[C@H]2C)OC)C)=O)O)=O)=O)=O plus octreotide LAR treatment, the patient experienced grade 1 hyperglycemia and grade 2 anemia, which ... | 9448188 |
Octreotide | C1=C2C(C[C@H]3C(N[C@@H](CCCCN)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(N[C@@H]([C@H](O)C)CO)=O)CSSC[C@@H](NC([C@@H](N)CC4=CC=CC=C4)=O)C(=O)N[C@@H](CC4C=CC=CC=4)C(N3)=O)=O)=O)=O)=CNC2=CC=C1 | Throughout the course of everolimus plus C1=C2C(C[C@H]3C(N[C@@H](CCCCN)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(N[C@@H]([C@H](O)C)CO)=O)CSSC[C@@H](NC([C@@H](N)CC4=CC=CC=C4)=O)C(=O)N[C@@H](CC4C=CC=CC=4)C(N3)=O)=O)=O)=O)=CNC2=CC=C1 LAR treatment, the patient experienced grade 1 hyperglycemia and grade 2 anemia, which were treated... | 9448188 |
Everolimus | [C@H](C[C@H]1C[C@H]([C@H](OCCO)CC1)OC)(C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C([C@@]2(O)[C@@H](CC[C@@H](C[C@H](OC)/C(=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@@H]([C@@H](/C(=C/[C@@H](C)C(=O)C1)C)O)OC)C)O2)C)=O | In December 2010, after 15 months of [C@H](C[C@H]1C[C@H]([C@H](OCCO)CC1)OC)(C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C([C@@]2(O)[C@@H](CC[C@@H](C[C@H](OC)/C(=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@@H]([C@@H](/C(=C/[C@@H](C)C(=O)C1)C)O)OC)C)O2)C)=O and octreotide LAR as sixth-line therapy, the patient continued to be asymptomatic ... | 9448188 |
Octreotide | [C@H]([C@@H](C)O)(CO)NC([C@H]1CSSC[C@H](C(N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(=O)N1)CCCCN)CC1=CNC2C1=CC=CC=2)=O)NC(=O)[C@H](CC1=CC=CC=C1)N)=O | In December 2010, after 15 months of everolimus and [C@H]([C@@H](C)O)(CO)NC([C@H]1CSSC[C@H](C(N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(=O)N1)CCCCN)CC1=CNC2C1=CC=CC=2)=O)NC(=O)[C@H](CC1=CC=CC=C1)N)=O LAR as sixth-line therapy, the patient continued to be asymptomatic and had a KPS of 90%. As... | 9448188 |
Everolimus | O(C)[C@@H]1C[C@@H](CC[C@H]1OCCO)C[C@H]([C@H]1OC([C@H]2N(CCCC2)C(=O)C(=O)[C@@]2(O[C@@H](CC[C@H]2C)C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C([C@@H]([C@H](O)/C(=C/[C@H](C(C1)=O)C)C)OC)=O)C)C)C)OC)O)=O)C | After more than 1 year of treatment benefit with O(C)[C@@H]1C[C@@H](CC[C@H]1OCCO)C[C@H]([C@H]1OC([C@H]2N(CCCC2)C(=O)C(=O)[C@@]2(O[C@@H](CC[C@H]2C)C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C([C@@H]([C@H](O)/C(=C/[C@H](C(C1)=O)C)C)OC)=O)C)C)C)OC)O)=O)C, during CT evaluation in March 2011, the patient's liver metastases were sho... | 9448188 |
Octreotide | O=C1[C@@H](NC(=O)[C@@H](NC([C@@H](NC(=O)[C@H](NC([C@@H](N)Cc2ccccc2)=O)CSSC[C@@H](NC(=O)[C@H]([C@H](O)C)N1)C(=O)N[C@@H]([C@H](O)C)CO)Cc1ccccc1)=O)Cc1c[nH]c2c1cccc2)CCCCN | After more than 1 year of treatment benefit with everolimus, during CT evaluation in March 2011, the patient's liver metastases were shown to have progressed. A diagnostic biopsy was repeated. However, it was possible only to confirm the high Ki-67 index and electron-dense granules containing synaptophysin and CgA. Mos... | 9448188 |
Everolimus | C1CCC[C@H]2C(=O)O[C@@H](CC([C@H](C)/C=C(\C)[C@H]([C@H](C([C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@H](C[C@@H]3CC[C@@H](C)[C@](C(=O)C(N21)=O)(O3)O)OC)=O)OC)O)=O)[C@H](C)C[C@@H]1CC[C@H]([C@H](OC)C1)OCCO | In the case presented here, a patient with high-grade pNET and 5 failed chemotherapy regimens was treated with C1CCC[C@H]2C(=O)O[C@@H](CC([C@H](C)/C=C(\C)[C@H]([C@H](C([C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@H](C[C@@H]3CC[C@@H](C)[C@](C(=O)C(N21)=O)(O3)O)OC)=O)OC)O)=O)[C@H](C)C[C@@H]1CC[C@H]([C@H](OC)C1)OCCO plus octreotid... | 9448188 |
Octreotide | C[C@H]([C@@H]1NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@H](NC([C@H](Cc2ccccc2)N)=O)CSSC[C@H](C(=O)N[C@@H]([C@H](O)C)CO)NC1=O)Cc1ccccc1)=O)Cc1c[nH]c2c1cccc2)=O)CCCCN)=O)O | In the case presented here, a patient with high-grade pNET and 5 failed chemotherapy regimens was treated with everolimus plus C[C@H]([C@@H]1NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@H](NC([C@H](Cc2ccccc2)N)=O)CSSC[C@H](C(=O)N[C@@H]([C@H](O)C)CO)NC1=O)Cc1ccccc1)=O)Cc1c[nH]c2c1cccc2)=O)CCCCN)=O)O LAR and achieved prolonged... | 9448188 |
Everolimus | [C@H]1(/C(=C/[C@@H](C)C(C[C@H](OC(=O)[C@H]2N(CCCC2)C(C([C@@]2(O[C@@H](CC[C@H]2C)C[C@H](OC)/C(C)=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]1OC)C)C)O)=O)=O)[C@@H](C[C@@H]1CC[C@H]([C@H](OC)C1)OCCO)C)=O)C)O | The combination of [C@H]1(/C(=C/[C@@H](C)C(C[C@H](OC(=O)[C@H]2N(CCCC2)C(C([C@@]2(O[C@@H](CC[C@H]2C)C[C@H](OC)/C(C)=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]1OC)C)C)O)=O)=O)[C@@H](C[C@@H]1CC[C@H]([C@H](OC)C1)OCCO)C)=O)C)O plus octreotide LAR demonstrated markedly improved clinical benefit compared with previous first-to fifth-... | 9448188 |
Octreotide | N([C@H]1C(N[C@H](C(=O)N[C@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)CO)[C@@H](C)O)CCCCN)=O)CC1=CNC2C1=CC=CC=2)CC1C=CC=CC=1)=O)C(=O)[C@@H](N)CC1C=CC=CC=1 | The combination of everolimus plus N([C@H]1C(N[C@H](C(=O)N[C@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)CO)[C@@H](C)O)CCCCN)=O)CC1=CNC2C1=CC=CC=2)CC1C=CC=CC=1)=O)C(=O)[C@@H](N)CC1C=CC=CC=1 LAR demonstrated markedly improved clinical benefit compared with previous first-to fifth-line treatment reg... | 9448188 |
Temozolomide | n1(nnc2n(cnc2C(=O)N)c1=O)C | The combination of everolimus plus octreotide LAR demonstrated markedly improved clinical benefit compared with previous first-to fifth-line treatment regimens administered to the patient (table 1). Partial radiologic response was achieved only at 12 weeks with fourth-line n1(nnc2n(cnc2C(=O)N)c1=O)C and capecitabine, b... | 9448188 |
Everolimus | C1(=C/[C@@H](C)C(=O)C[C@@H]([C@@H](C[C@H]2C[C@H]([C@H](OCCO)CC2)OC)C)OC([C@H]2N(CCCC2)C(C(=O)[C@]2([C@H](C)CC[C@@H](C[C@@H](/C(=C/C=C/C=C/[C@@H](C)C[C@H](C(=O)[C@@H]([C@@H]/1O)OC)C)C)OC)O2)O)=O)=O)C | The patient in this study derived a clinical benefit with C1(=C/[C@@H](C)C(=O)C[C@@H]([C@@H](C[C@H]2C[C@H]([C@H](OCCO)CC2)OC)C)OC([C@H]2N(CCCC2)C(C(=O)[C@]2([C@H](C)CC[C@@H](C[C@@H](/C(=C/C=C/C=C/[C@@H](C)C[C@H](C(=O)[C@@H]([C@@H]/1O)OC)C)C)OC)O2)O)=O)=O)C-based therapy similar to the median values reported in the RADI... | 9448188 |
Octreotide | C1(=O)N[C@H](C(N[C@@H](CC2=CNC3C2=CC=CC=3)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](C(=O)N[C@@H]([C@H](O)C)CO)CSSC[C@H]1NC([C@@H](N)CC1=CC=CC=C1)=O)=O)[C@H](O)C)CCCCN)=O)CC1C=CC=CC=1 | The patient in this study derived a clinical benefit with everolimus-based therapy similar to the median values reported in the RADIANT trials, which enrolled patients with lowgrade NET [10]. In the phase III RADIANT-3 trial, patients with pNET receiving 10 mg everolimus achieved a median PFS of 11 months, and 34% of p... | 9448188 |
Octreotide | C12NC=C(C1=CC=CC=2)C[C@@H]1NC([C@H](CC2C=CC=CC=2)NC([C@H](NC([C@@H](N)CC2=CC=CC=C2)=O)CSSC[C@H](C(=O)N[C@H](CO)[C@H](O)C)NC([C@@H](NC(=O)[C@H](CCCCN)NC1=O)[C@@H](C)O)=O)=O)=O | Neither RADIANT-3 nor RADIANT-2 included objective tumor response as a secondary endpoint, whereas the PROMID study was a phase III trial investigating the antitumor effects of C12NC=C(C1=CC=CC=2)C[C@@H]1NC([C@H](CC2C=CC=CC=2)NC([C@H](NC([C@@H](N)CC2=CC=CC=C2)=O)CSSC[C@H](C(=O)N[C@H](CO)[C@H](O)C)NC([C@@H](NC(=O)[C@H](... | 9448188 |
Everolimus | C1=C/C=C/[C@H](C[C@@H](C)C(=O)[C@@H]([C@H](O)/C(C)=C/[C@H](C(C[C@@H]([C@@H](C[C@H]2C[C@H]([C@H](OCCO)CC2)OC)C)OC([C@@H]2CCCCN2C(=O)C(=O)[C@]2([C@@H](CC[C@H](O2)C[C@H](OC)/C(C)=C/1)C)O)=O)=O)C)OC)C | Our patient tolerated C1=C/C=C/[C@H](C[C@@H](C)C(=O)[C@@H]([C@H](O)/C(C)=C/[C@H](C(C[C@@H]([C@@H](C[C@H]2C[C@H]([C@H](OCCO)CC2)OC)C)OC([C@@H]2CCCCN2C(=O)C(=O)[C@]2([C@@H](CC[C@H](O2)C[C@H](OC)/C(C)=C/1)C)O)=O)=O)C)OC)C plus octreotide LAR as a sixth-line regimen for the management of high-grade pNET with minimal toxici... | 9448188 |
Octreotide | C1(N[C@H](C(=O)N[C@H](CSSC[C@@H](NC([C@H](Cc2ccccc2)N)=O)C(=O)N[C@@H](Cc2ccccc2)C(N[C@H](C(N[C@H]1CCCCN)=O)Cc1c[nH]c2c1cccc2)=O)C(=O)N[C@H](CO)[C@H](O)C)[C@@H](C)O)=O | Our patient tolerated everolimus plus C1(N[C@H](C(=O)N[C@H](CSSC[C@@H](NC([C@H](Cc2ccccc2)N)=O)C(=O)N[C@@H](Cc2ccccc2)C(N[C@H](C(N[C@H]1CCCCN)=O)Cc1c[nH]c2c1cccc2)=O)C(=O)N[C@H](CO)[C@H](O)C)[C@@H](C)O)=O LAR as a sixth-line regimen for the management of high-grade pNET with minimal toxicity, similar to what has been r... | 9448188 |
Everolimus | C[C@@H]1/C=C(\C)[C@H]([C@H](C(=O)[C@@H](C[C@@H](/C=C/C=C/C=C(/[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](C(C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C@@H](C[C@@H]3CC[C@@H](OCCO)[C@@H](C3)OC)C)CC1=O)=O)(O)O2)C)C)C)OC)O | The effect of C[C@@H]1/C=C(\C)[C@H]([C@H](C(=O)[C@@H](C[C@@H](/C=C/C=C/C=C(/[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](C(C(=O)N3CCCC[C@H]3C(=O)O[C@H]([C@@H](C[C@@H]3CC[C@@H](OCCO)[C@@H](C3)OC)C)CC1=O)=O)(O)O2)C)C)C)OC)O in poorly differentiated tumors is unknown; these tumors are usually excluded from clinical trials because o... | 9448188 |
Cisplatin | N.N.Cl[Pt]Cl | The effect of everolimus in poorly differentiated tumors is unknown; these tumors are usually excluded from clinical trials because of their aggressiveness. However, these tumors have a better response rate to chemotherapy and may express more mTOR than welldifferentiated tumors, and mTOR elevation appears to be consis... | 9448188 |
Etoposide | c1c2c(cc3[C@H]([C@@H]4[C@@H]([C@@H](c13)c1cc(c(O)c(c1)OC)OC)C(OC4)=O)O[C@@H]1O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]1O)C)OCO2 | The effect of everolimus in poorly differentiated tumors is unknown; these tumors are usually excluded from clinical trials because of their aggressiveness. However, these tumors have a better response rate to chemotherapy and may express more mTOR than welldifferentiated tumors, and mTOR elevation appears to be consis... | 9448188 |
Everolimus | [C@H](C)([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@@]2(O)[C@@H](CC[C@H](O2)C[C@@H](/C(=C/C=C/C=C/[C@@H](C)C[C@H](C([C@H](OC)[C@@H](/C(=C/[C@H](C(C1)=O)C)C)O)=O)C)C)OC)C)C[C@H]1C[C@H]([C@H](OCCO)CC1)OC | Treatment with [C@H](C)([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@@]2(O)[C@@H](CC[C@H](O2)C[C@@H](/C(=C/C=C/C=C/[C@@H](C)C[C@H](C([C@H](OC)[C@@H](/C(=C/[C@H](C(C1)=O)C)C)O)=O)C)C)OC)C)C[C@H]1C[C@H]([C@H](OCCO)CC1)OC plus octreotide LAR demonstrated definitive clinical response and prolonged PFS of more than 15 months in th... | 9448188 |
Octreotide | N1[C@H](C(=O)N[C@H](CSSC[C@@H](NC(=O)[C@H](Cc2ccccc2)N)C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C1=O)=O)Cc1c[nH]c2c1cccc2)=O)Cc1ccccc1)=O)C(=O)N[C@H](CO)[C@H](O)C)[C@@H](C)O | Treatment with everolimus plus N1[C@H](C(=O)N[C@H](CSSC[C@@H](NC(=O)[C@H](Cc2ccccc2)N)C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C1=O)=O)Cc1c[nH]c2c1cccc2)=O)Cc1ccccc1)=O)C(=O)N[C@H](CO)[C@H](O)C)[C@@H](C)O LAR demonstrated definitive clinical response and prolonged PFS of more than 15 months in this heavily pretreated patient ... | 9448188 |
Serina | OC([C@@H](N)CO)=O | However, in some applications, the objective is not individual level predictions, but rather to learn about population-level distributions of a given outcome.Examples include sentiment analysis for Twitter users (Giachanou and Crestani, 2016), estimating the prevalence of chronic fatigue syndrome (Valdez et al., 2018),... | 210718461 |
Mimic | C1C(C)=CC(=CC=1C)C(=O)N(C(C)(C)C)NC(C1=CC=C(CC)C=C1)=O | To C1C(C)=CC(=CC=1C)C(=O)N(C(C)(C)C)NC(C1=CC=C(CC)C=C1)=O the motivating verbal autopsy application, we used N = 1000, n = 300, C = 5, p L = E L (y r ) = | 210718461 |
Serina | OC[C@@H](C(O)=O)N | We now apply GBQL to the PHMRC dataset introduced in Section 1.The number of observations within India, Mexico, Philippines, and Tanzania are 2973, 1586, 1259, and 2023, respectively.To address countryspecific dataset shift, for each country, we used the three remaining countries as training data for four methods commo... | 210718461 |
Thiotepa | N1(P(=S)(N2CC2)N2CC2)CC1 | Several surgical techniques are available for treating pterygium, such as bare sclera, simple conjunctival closure, sliding conjunctival flaps, and conjunctival autografts. Adjunctive therapies, such as pos toperative beta radiation or N1(P(=S)(N2CC2)N2CC2)CC1 drops and intraoperative mitomycin C, can be used to preven... | 21338758 |
Mitomycin | C1(C)=C(C(C2[C@H]([C@@]3(OC)[C@@H]4[C@@H](N4)CN3C=2C1=O)COC(=O)N)=O)N | Several surgical techniques are available for treating pterygium, such as bare sclera, simple conjunctival closure, sliding conjunctival flaps, and conjunctival autografts. Adjunctive therapies, such as pos toperative beta radiation or thiotepa drops and intraoperative C1(C)=C(C(C2[C@H]([C@@]3(OC)[C@@H]4[C@@H](N4)CN3C=... | 21338758 |
Mitomycin | O=C1C(=C(C(C2=C1N1[C@]([C@@H]2COC(N)=O)(OC)[C@@H]2[C@H](C1)N2)=O)N)C | Severe scleral dellen (SD) is a rare complication during the early postoperative period following pterygium surgery. The few reports describing this condition are all related to the bare sclera technique without adjunctive therapy (2,3) or with intraoperative O=C1C(=C(C(C2=C1N1[C@]([C@@H]2COC(N)=O)(OC)[C@@H]2[C@H](C1)N... | 21338758 |
Lidocaine | N(C(=O)CN(CC)CC)c1c(cccc1C)C | A 45-year-old bricklayer with a primary pterygium on the nasal side of his right eye underwent surgical excision with minimal cauterization of episcleral vessels and simple conjunctival closure with two stitches (7/0 silk). The procedure was carried out under topical and subconjunctival anesthesia (N(C(=O)CN(CC)CC)c1c(... | 21338758 |
Epinephrine | C1(C=CC([C@H](CNC)O)=CC=1O)O | A 45-year-old bricklayer with a primary pterygium on the nasal side of his right eye underwent surgical excision with minimal cauterization of episcleral vessels and simple conjunctival closure with two stitches (7/0 silk). The procedure was carried out under topical and subconjunctival anesthesia (lidocaine 2% and C1(... | 21338758 |
Dexamethasone | C[C@@]12C=CC(C=C2CC[C@H]2[C@@H]3C[C@H]([C@](C(CO)=O)([C@]3(C[C@@H]([C@@]21F)O)C)O)C)=O | A 45-year-old bricklayer with a primary pterygium on the nasal side of his right eye underwent surgical excision with minimal cauterization of episcleral vessels and simple conjunctival closure with two stitches (7/0 silk). The procedure was carried out under topical and subconjunctival anesthesia (lidocaine 2% and epi... | 21338758 |
Chloramphenicol | C(N[C@H](CO)[C@H](O)c1ccc(cc1)[N+](=O)[O-])(=O)C(Cl)Cl | A 45-year-old bricklayer with a primary pterygium on the nasal side of his right eye underwent surgical excision with minimal cauterization of episcleral vessels and simple conjunctival closure with two stitches (7/0 silk). The procedure was carried out under topical and subconjunctival anesthesia (lidocaine 2% and epi... | 21338758 |
Gentamicin | NC1CC(N)C(OC2OC(C(NC)C)CCC2N)C(C1OC1OC[C@](C(C1O)NC)(C)O)O | One week later, the patient arrived at the emergency department complaining of moderate pain and a black dot in his right eye. His best corrected visual acuity was 10/10 and intraocular pressure was 15 mmHg. Slit lamp examination revealed severe scleral thinning reaching the choroid (Figure 1). The conjunctival sutures... | 21338758 |
Carmellose | C(O)(C)=O.OC(C=O)C(O)C(C(O)CO)O | One week later, the patient arrived at the emergency department complaining of moderate pain and a black dot in his right eye. His best corrected visual acuity was 10/10 and intraocular pressure was 15 mmHg. Slit lamp examination revealed severe scleral thinning reaching the choroid (Figure 1). The conjunctival sutures... | 21338758 |
Vasoconstrictor | C1C(=C(O)C=CC=1[C@H](CNC)O)O | Whereas the growth of blood vessels in the wound bed is considered to contribute to pterygium recurrence, some authors have recommended cauterization of episcleral vessels, especially at the limbus. However, it appears that coagulation of the episcleral vessels, which do not bleed, neither avoids recurrences nor contri... | 21338758 |
Epinephrine | C1C([C@H](CNC)O)=CC(O)=C(O)C=1 | Whereas the growth of blood vessels in the wound bed is considered to contribute to pterygium recurrence, some authors have recommended cauterization of episcleral vessels, especially at the limbus. However, it appears that coagulation of the episcleral vessels, which do not bleed, neither avoids recurrences nor contri... | 21338758 |
Ceftriaxone | C1(N=C(N(NC1=O)C)SCC1=C(N2C([C@@H](NC(=O)/C(=N/OC)C3=CSC(=N3)N)C2SC1)=O)C(O)=O)=O | Culture results were collected, and susceptibility results were analyzed.Organisms in this study could have been isolated from any source including skin swabs, tissue cultures following surgical excision, bronchoalveolar lavage, sputum, tracheal aspirate, urine, bone, or blood.Due to the retrospective nature of the stu... | 271556193 |
Cefotaxime | [C@@H]1(NC(=O)C(=NOC)C2=CSC(N)=N2)C(N2[C@H]1SCC(COC(=O)C)=C2C(O)=O)=O | Culture results were collected, and susceptibility results were analyzed.Organisms in this study could have been isolated from any source including skin swabs, tissue cultures following surgical excision, bronchoalveolar lavage, sputum, tracheal aspirate, urine, bone, or blood.Due to the retrospective nature of the stu... | 271556193 |
Ceftazidime | C1(C[N+]2=CC=CC=C2)CS[C@H]2[C@@H](NC(/C(=N\OC(C(O)=O)(C)C)C3N=C(N)SC=3)=O)C(N2C=1C(=O)[O-])=O | Culture results were collected, and susceptibility results were analyzed.Organisms in this study could have been isolated from any source including skin swabs, tissue cultures following surgical excision, bronchoalveolar lavage, sputum, tracheal aspirate, urine, bone, or blood.Due to the retrospective nature of the stu... | 271556193 |
Carbapenem | C1N2[C@H](CC=1)CC2=O | Culture results were collected, and susceptibility results were analyzed.Organisms in this study could have been isolated from any source including skin swabs, tissue cultures following surgical excision, bronchoalveolar lavage, sputum, tracheal aspirate, urine, bone, or blood.Due to the retrospective nature of the stu... | 271556193 |
Penicillins | CC1(C)[C@@H](N2[C@H](S1)[C@H](NC(Cc1ccccc1)=O)C2)C(=O)O | Culture results were collected, and susceptibility results were analyzed.Organisms in this study could have been isolated from any source including skin swabs, tissue cultures following surgical excision, bronchoalveolar lavage, sputum, tracheal aspirate, urine, bone, or blood.Due to the retrospective nature of the stu... | 271556193 |
Cephalosporins | C(=O)(O)C1N2C([C@@H](NC(=O)CCC[C@H](C(=O)O)N)[C@H]2SCC=1COC(=O)C)=O | Culture results were collected, and susceptibility results were analyzed.Organisms in this study could have been isolated from any source including skin swabs, tissue cultures following surgical excision, bronchoalveolar lavage, sputum, tracheal aspirate, urine, bone, or blood.Due to the retrospective nature of the stu... | 271556193 |
Carbapenems | N12C(C(=O)O)=CCC1CC2=O | Culture results were collected, and susceptibility results were analyzed.Organisms in this study could have been isolated from any source including skin swabs, tissue cultures following surgical excision, bronchoalveolar lavage, sputum, tracheal aspirate, urine, bone, or blood.Due to the retrospective nature of the stu... | 271556193 |
Mafenide | c1(CN)ccc(S(N)(=O)=O)cc1 | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Silver sulfadiazine | c1cnc([N-]S(c2ccc(cc2)N)(=O)=O)nc1.[Ag+] | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Sulfadiazine | c1cc(N)ccc1S(Nc1ncccn1)(=O)=O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Mupirocin | O[C@@H](C)[C@H](C)[C@H]1[C@@H](O1)C[C@H]1CO[C@H]([C@H](O)[C@@H]1O)C/C(=C/C(OCCCCCCCCC(O)=O)=O)C | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Chlorohexidine | Clc1ccc(N/C(=N/C(=NCCCCCCN=C(/N=C(\N)Nc2ccc(Cl)cc2)N)N)N)cc1 | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Gluconate | O[C@H]([C@H](C(=O)[O-])O)[C@H](O)[C@H](O)CO | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Cefazolin | c1nnnn1CC(=O)N[C@@H]1C(N2[C@@H]1SCC(=C2C(O)=O)CSc1sc(C)nn1)=O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Ceftriaxone | O=c1c(nc(n(C)[nH]1)SCC1CSC2[C@@H](C(N2C=1C(O)=O)=O)NC(/C(=N/OC)c1csc(N)n1)=O)=O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Ampicillin | C1(C)(C)[C@@H](N2C(=O)[C@@H](NC([C@H](N)C3=CC=CC=C3)=O)[C@H]2S1)C(=O)O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Ampicillin-sulbactam | C12C(S(C(C)(C1C(=O)O)C)(=O)=O)CC2=O.O=C(NC1C2SC(C(N2C1=O)C(=O)O)(C)C)C(N)C1=CC=CC=C1 | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Piperacillin-tazobactam | O=C1N(CCN(C1=O)CC)C(=O)N[C@H](C(=O)N[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)[O-])c1ccccc1.[C@@]1(Cn2nncc2)(C)S([C@@H]2CC(=O)N2[C@H]1C(O)=O)(=O)=O.[Na+] | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Cefepime | O=C(/C(=N/OC)C1=CSC(=N1)N)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(CSC12)C[N+]1(CCCC1)C | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Carbapenems | O=C(O)C1=CCC2N1C(C2)=O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Meropenem | [C@@H]1(NC[C@H](C1)SC1=C(C(O)=O)N2C([C@H]([C@H](O)C)[C@H]2[C@H]1C)=O)C(N(C)C)=O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Ertapenem | [C@H]([C@H]1C(N2[C@@H]1[C@H](C(=C2C(O)=O)S[C@H]1C[C@H](NC1)C(NC1=CC=CC(C(=O)O)=C1)=O)C)=O)(C)O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Ciprofloxacin | C1CN(c2cc3c(cc2F)c(c(cn3C2CC2)C(O)=O)=O)CCN1 | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Linezolid | C1=C(C=CC(=C1F)N1CCOCC1)N1C(O[C@@H](CNC(C)=O)C1)=O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Amikacin | [C@H](C(=O)N[C@H]1[C@H](O[C@@H]2[C@@H]([C@@H](N)[C@@H]([C@H](O2)CO)O)O)[C@H]([C@H](O[C@H]2O[C@H](CN)[C@H]([C@@H]([C@H]2O)O)O)[C@@H](N)C1)O)(O)CCN | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Gentamicin | C1(OC2C(O)C(OC3OC[C@](C(C3O)NC)(C)O)C(N)CC2N)C(N)CCC(O1)C(NC)C | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Tobramycin | C([C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@@H]([C@H]([C@H](N)[C@H]3O)O)CO)[C@H]2O)[C@@H](C[C@@H]1O)N)N | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Ceftolozane-tazobactam | S1(=O)(=O)[C@H]2N([C@@H](C(=O)O)[C@]1(C)Cn1ccnn1)C(=O)C2.O=C(C1N2[C@H](SCC=1C[n+]1cc(c(N)n1C)NC(=O)NCCN)[C@@H](C2=O)NC(=O)/C(=N/OC(C)(C(=O)O)C)c1nsc(N)n1)[O-].OS(=O)(O)=O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Metronidazole | C1=C(N(CCO)C(=N1)C)[N+]([O-])=O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Doxycycline | O=C1C(C(N)=O)=C([C@]2(C(=O)C3[C@@H]([C@@H](C)C4C=CC=C(C=4C=3O)O)[C@H](O)[C@H]2[C@@H]1N(C)C)O)O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Minocycline | C12=C(C=CC(O)=C1C(O)=C1C(=O)[C@@]3(O)[C@@H](C[C@@H]1C2)[C@@H](C(C(C(N)=O)=C3O)=O)N(C)C)N(C)C | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Sulfamethoxazole-trimethoprim | C1C(NS(=O)(=O)C2=CC=C(N)C=C2)=NOC=1C.C1N=C(N)N=C(C=1CC1=CC(=C(OC)C(=C1)OC)OC)N | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Fluconazole | C1(F)=CC(F)=C(C=C1)C(O)(CN1N=CN=C1)CN1C=NC=N1 | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Micafungin | N1C([C@H]2N(C(=O)[C@H]([C@H](O)C)NC([C@@H](NC(C3C=CC(C4=NOC(C5C=CC(OCCCCC)=CC=5)=C4)=CC=3)=O)C[C@H]([C@H](NC([C@@H]3[C@H]([C@H](CN3C([C@H]([C@H](O)CC(=O)N)NC([C@@H]1[C@H](O)[C@@H](O)C1=CC(=C(C=C1)O)OS(=O)(=O)O)=O)=O)C)O)=O)O)O)=O)C[C@H](O)C2)=O | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Isavuconazole | c1([C@@](Cn2ncnc2)([C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)O)c(F)ccc(F)c1 | Hierarchical data were collected according to patient, pathogen, and date of infection.Exposures of topical and systemic antimicrobials were tracked over time.Exposure was recorded at the pathogen level and was defined as exposure to any patient site (i.e., exposure at the patient level) prior to each culture obtainmen... | 271556193 |
Cephalosporins | O=C(O)C1N2C([C@@H](NC(=O)CCC[C@H](C(O)=O)N)[C@H]2SCC=1COC(=O)C)=O | During this study period, the institution's microbiology laboratory utilized the Brucker MALDI Biotyper for the identification of bacteria and yeast.This system uses mass spectrometry to determine the proteomic fingerprints of microorganisms and compares these to the research-use-only database for microbial identificat... | 271556193 |
Carbapenem | [C@@H]12N(C(=O)C2)C=CC1 | During this study period, the institution's microbiology laboratory utilized the Brucker MALDI Biotyper for the identification of bacteria and yeast.This system uses mass spectrometry to determine the proteomic fingerprints of microorganisms and compares these to the research-use-only database for microbial identificat... | 271556193 |
Meropenem | [C@H](C)(O)[C@H]1C(=O)N2C(C(O)=O)=C([C@H](C)[C@H]12)S[C@H]1C[C@H](NC1)C(=O)N(C)C | During this study period, the institution's microbiology laboratory utilized the Brucker MALDI Biotyper for the identification of bacteria and yeast.This system uses mass spectrometry to determine the proteomic fingerprints of microorganisms and compares these to the research-use-only database for microbial identificat... | 271556193 |
Ertapenem | C[C@@H](O)[C@H]1C(N2C(C(O)=O)=C(S[C@H]3C[C@H](NC3)C(=O)NC3C=C(C=CC=3)C(=O)O)[C@@H]([C@@H]21)C)=O | During this study period, the institution's microbiology laboratory utilized the Brucker MALDI Biotyper for the identification of bacteria and yeast.This system uses mass spectrometry to determine the proteomic fingerprints of microorganisms and compares these to the research-use-only database for microbial identificat... | 271556193 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.